SINGAPORE'S Novena Global Healthcare has bagged US$20 million in investment from Sinopharm Capital and Cedarlake Capital Group.
The US$20 million investment will be used to grow the Singapore aesthetic healthcare firm's existing business in China and South-east Asia. This is while leveraging on Sinopharm Capital’s network and resources for its China expansion. Nelson Loh, executive chairman and co-founder of DORR Group and Novena Global Lifecare, said the company will continue to innovate and disrupt the lifecare industry around the region.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: